<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chen, Nanhui</style></author><author><style face="normal" font="default" size="100%">Wang, Zengjun</style></author><author><style face="normal" font="default" size="100%">Chen, Ming</style></author><author><style face="normal" font="default" size="100%">Ma, Qi</style></author><author><style face="normal" font="default" size="100%">He, Yi</style></author><author><style face="normal" font="default" size="100%">Wang, Yujie</style></author><author><style face="normal" font="default" size="100%">Li, Xin</style></author><author><style face="normal" font="default" size="100%">Qiu, Mingxing</style></author><author><style face="normal" font="default" size="100%">Shi, Lei</style></author><author><style face="normal" font="default" size="100%">Zhu, Shaoxing</style></author><author><style face="normal" font="default" size="100%">Xie, Qun</style></author><author><style face="normal" font="default" size="100%">Liu, Xiuheng</style></author><author><style face="normal" font="default" size="100%">Shi, Benkang</style></author><author><style face="normal" font="default" size="100%">Lin, Guowen</style></author><author><style face="normal" font="default" size="100%">Yang, Weizhong</style></author><author><style face="normal" font="default" size="100%">Liao, Yongbin</style></author><author><style face="normal" font="default" size="100%">Zhang, Haibin</style></author><author><style face="normal" font="default" size="100%">Wang, Shusheng</style></author><author><style face="normal" font="default" size="100%">Li, Jiexian</style></author><author><style face="normal" font="default" size="100%">Wang, Shaogang</style></author><author><style face="normal" font="default" size="100%">Dong, Lijun</style></author><author><style face="normal" font="default" size="100%">Chen, Hui</style></author><author><style face="normal" font="default" size="100%">Lu, Jiaju</style></author><author><style face="normal" font="default" size="100%">Cheng, Yongyi</style></author><author><style face="normal" font="default" size="100%">Zhang, Xiaoping</style></author><author><style face="normal" font="default" size="100%">Ma, Lulin</style></author><author><style face="normal" font="default" size="100%">Zhou, Liqun</style></author><author><style face="normal" font="default" size="100%">Wang, He</style></author><author><style face="normal" font="default" size="100%">Li, Shen</style></author><author><style face="normal" font="default" size="100%">Ye, Dingwei</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Biology &amp;amp; Medicine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023-12-15 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1047-1059</style></pages><doi><style  face="normal" font="default" size="100%">10.20892/j.issn.2095-3941.2023.0335</style></doi><volume><style face="normal" font="default" size="100%">20</style></volume><issue><style face="normal" font="default" size="100%">12</style></issue><abstract><style  face="normal" font="default" size="100%">Objective: Real-word data on long-acting luteinizing hormone-releasing hormone (LHRH) agonists in Chinese patients with prostate cancer are limited. This study aimed to determine the real-world effectiveness and safety of the LHRH agonist, goserelin, particularly the long-acting 10.8-mg depot formulation, and the follow-up patterns among Chinese prostate cancer patients.Methods: This was a multicenter, prospective, observational study in hormone treatment-naïve patients with localized or locally advanced prostate cancer who were prescribed goserelin 10.8-mg depot every 12 weeks or 3.6-mg depot every 4 weeks with or without an anti-androgen. The patients had follow-up evaluations for 26 weeks. The primary outcome was the effectiveness of goserelin in reducing serum testosterone and prostate-specific antigen (PSA) levels. The secondary outcomes included testosterone and PSA levels, attainment of chemical castration (serum testosterone &lt;50 ng/dL), and goserelin safety. The exploratory outcome was the monitoring pattern for serum testosterone and PSA. All analyses were descriptive.Results: Between September 2017 and December 2019, a total of 294 eligible patients received ≥ 1 dose of goserelin; 287 patients (97.6%) were treated with goserelin 10.8-mg depot. At week 24 ± 2, the changes from baseline [standard deviation (95% confidence interval)] in serum testosterone (n = 99) and PSA (n = 131) were −401.0 ng/dL [308.4 ng/dL (−462.5, −339.5 ng/dL)] and −35.4 ng/mL [104.4 ng/mL (−53.5, −17.4 ng/mL)], respectively. Of 112 evaluable patients, 100 (90.2%) achieved a serum testosterone level &lt; 50 ng/dL. Treatment-emergent adverse events (TEAEs) and severe TEAEs occurred in 37.1% and 10.2% of patients, respectively. The mean testing frequency (standard deviation) was 1.6 (1.5) for testosterone and 2.2 (1.6) for PSA.Conclusions: Goserelin 10.8-mg depot effectively achieved and maintained castration and was well-tolerated in Chinese patients with localized and locally advanced prostate cancer.The data generated in this study are available upon reasonable request from the corresponding author.</style></abstract></record></records></xml>